Matt Miksic
Stock Analyst at Barclays
(3.61)
# 720
Out of 5,182 analysts
345
Total ratings
55.6%
Success rate
4.05%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ISRG Intuitive Surgical | Maintains: Overweight | $712 → $651 | $481.25 | +35.27% | 10 | Apr 23, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $100 → $96 | $65.70 | +46.12% | 22 | Apr 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $144 → $143 | $91.30 | +56.63% | 34 | Apr 20, 2026 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $234 → $255 | $229.28 | +11.22% | 17 | Apr 15, 2026 | |
| HUMA Humacyte | Maintains: Overweight | $3.5 → $1.5 | $0.71 | +110.82% | 2 | Apr 8, 2026 | |
| MDT Medtronic | Maintains: Overweight | $118 → $120 | $83.40 | +43.88% | 26 | Apr 1, 2026 | |
| MMED MiniMed Group | Initiates: Overweight | $26 | $13.42 | +93.74% | 1 | Apr 1, 2026 | |
| COO The Cooper Companies | Maintains: Overweight | $98 → $103 | $66.21 | +55.57% | 3 | Mar 6, 2026 | |
| LIVN LivaNova | Maintains: Equal-Weight | $67 → $73 | $65.12 | +12.10% | 10 | Feb 27, 2026 | |
| ALC Alcon | Maintains: Equal-Weight | $86 → $90 | $76.32 | +17.92% | 11 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $118 → $123 | $95.21 | +29.19% | 17 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $20 | $16.03 | +24.77% | 7 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $71 → $72 | $63.54 | +13.31% | 10 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $18.32 | +36.46% | 24 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $104 → $100 | $92.79 | +7.77% | 10 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $202 | $155.72 | +29.72% | 2 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $86 → $87 | $70.45 | +23.49% | 2 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $103 → $104 | $80.07 | +29.89% | 32 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $316 → $274 | $193.74 | +41.43% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $12 | $4.21 | +185.04% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $27 | $10.43 | +158.87% | 5 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $55 | $21.08 | +160.91% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1.5 → $31 | $7.01 | +342.23% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $330.24 | +37.17% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $14.33 | +46.55% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $5.71 | +285.29% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $78.30 | +27.71% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $191.76 | +117.98% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $15.33 | +82.65% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $12.02 | +457.40% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $10.71 | +712.32% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $2.38 | +950.42% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $9.94 | +141.45% | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $3.35 | +168.66% | 1 | Dec 12, 2016 |
Intuitive Surgical
Apr 23, 2026
Maintains: Overweight
Price Target: $712 → $651
Current: $481.25
Upside: +35.27%
Boston Scientific
Apr 23, 2026
Maintains: Overweight
Price Target: $100 → $96
Current: $65.70
Upside: +46.12%
Abbott Laboratories
Apr 20, 2026
Maintains: Overweight
Price Target: $144 → $143
Current: $91.30
Upside: +56.63%
Johnson & Johnson
Apr 15, 2026
Maintains: Equal-Weight
Price Target: $234 → $255
Current: $229.28
Upside: +11.22%
Humacyte
Apr 8, 2026
Maintains: Overweight
Price Target: $3.5 → $1.5
Current: $0.71
Upside: +110.82%
Medtronic
Apr 1, 2026
Maintains: Overweight
Price Target: $118 → $120
Current: $83.40
Upside: +43.88%
MiniMed Group
Apr 1, 2026
Initiates: Overweight
Price Target: $26
Current: $13.42
Upside: +93.74%
The Cooper Companies
Mar 6, 2026
Maintains: Overweight
Price Target: $98 → $103
Current: $66.21
Upside: +55.57%
LivaNova
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $67 → $73
Current: $65.12
Upside: +12.10%
Alcon
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $86 → $90
Current: $76.32
Upside: +17.92%
Feb 25, 2026
Maintains: Overweight
Price Target: $118 → $123
Current: $95.21
Upside: +29.19%
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $17 → $20
Current: $16.03
Upside: +24.77%
Feb 13, 2026
Maintains: Underweight
Price Target: $71 → $72
Current: $63.54
Upside: +13.31%
Feb 13, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $18.32
Upside: +36.46%
Feb 12, 2026
Maintains: Underweight
Price Target: $104 → $100
Current: $92.79
Upside: +7.77%
Feb 11, 2026
Reinstates: Overweight
Price Target: $202
Current: $155.72
Upside: +29.72%
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $86 → $87
Current: $70.45
Upside: +23.49%
Jan 12, 2026
Maintains: Overweight
Price Target: $103 → $104
Current: $80.07
Upside: +29.89%
Jan 12, 2026
Downgrades: Underweight
Price Target: $316 → $274
Current: $193.74
Upside: +41.43%
Jan 9, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $4.21
Upside: +185.04%
Jan 7, 2026
Maintains: Overweight
Price Target: $23 → $27
Current: $10.43
Upside: +158.87%
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $21.08
Upside: +160.91%
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $7.01
Upside: +342.23%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $330.24
Upside: +37.17%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.33
Upside: +46.55%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $5.71
Upside: +285.29%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $78.30
Upside: +27.71%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $191.76
Upside: +117.98%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $15.33
Upside: +82.65%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $12.02
Upside: +457.40%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $10.71
Upside: +712.32%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $2.38
Upside: +950.42%
Oct 10, 2017
Maintains: Buy
Price Target: $26 → $24
Current: $9.94
Upside: +141.45%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $3.35
Upside: +168.66%